Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe.

Date publication

janvier 2022

Journal

Crohn's & colitis 360

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Huynh L, Hass S, Peyrin-Biroulet L, Duh MS, Sipsma H, Cheng M, Lax A, Nag A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36777550

Résumé

With many options available for treating inflammatory bowel disease (IBD) in Europe, this study sought to characterize physician treatment preferences and real-world treatment patterns in patients with moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD).

Mots clés

Crohn’s disease, biological therapy, biosimilar pharmaceuticals, physicians’ practice patterns, ulcerative colitis

Référence

Crohns Colitis 360. 2022 01;4(1):otac001